Top

Published in:

Open Access 01-12-2014 | Research

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Authors: Vincent Peter Collins, Koichi Ichimura, Ying Di, Danita Pearson, Ray Chan, Lindsay C Thompson, Rhian Gabe, Michael Brada, Sally P Stenning

Published in: Acta Neuropathologica Communications | Issue 1/2014

Abstract

We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m²/day) schedule and a 21-day (100 mg/m²/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy.

354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for some or all parts of the study. Genome-wide array comparative genomic hybridisation (aCGH), mutation analysis of IDH1/2 and TP53 and methylation analyses of the MGMT CpG-island was done.

84% of grade III tumours and 17% of grade IV had IDH1 or IDH2 mutations that conferred a better prognosis in both; MGMT methylation (defined as average value across 16 CpGs ≥ 10%) occurred in 75% of tumours and was also associated with improved survival. Both were of independent prognostic value after accounting for clinical factors and tumour grade. None of the molecular changes investigated gave clear evidence of a predictive benefit of TMZ over PCV or 21-day TMZ over 5-day TMZ although power was limited and a role for MGMT methylation could not be ruled out. Loss of 1p and 19q was seen in only 4 patients although hemizygous loss of 1p36 occurred in 20%.

The findings support reports that IDH1/2 mutations and MGMT methylation can be used in addition to tumour grade and clinical factors to predict survival in patients with recurrent high grade gliomas when treated with any of the therapy regimes used.

Available only for authorised users

Stupp R, van den Bent MJ, Hegi ME: Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005, 5(3):198–206. 10.1007/s11910-005-0047-7CrossRefPubMed

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997–1003. doi:10.1056/NEJMoa043331 10.1056/NEJMoa043331CrossRefPubMed

Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D: Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012, 118(17):4201–4211. doi:10.1002/cncr.27392 10.1002/cncr.27392CrossRefPubMed

Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M: Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 2013, 31(32):4076–4084. doi:10.1200/JCO.2013.49.6067 10.1200/JCO.2013.49.6067CrossRefPubMedPubMedCentral

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, Society NOASGoN-oWGoGC: Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13(7):707–715. doi:10.1016/S1470–2045(12)70164-X 10.1016/S1470-2045(12)70164-XCrossRefPubMed

Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R: Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012, 13(9):916–926. 10.1016/S1470-2045(12)70265-6CrossRefPubMed

Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K, Beall S, Collins VP, Lee SM: Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010, 28(30):4601–4608. doi:10.1200/JCO.2009.27.1932 10.1200/JCO.2009.27.1932CrossRefPubMed

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013, 31(3):337–343. doi:10.1200/JCO.2012.43.2674 10.1200/JCO.2012.43.2674CrossRefPubMed

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013, 31(3):344–350. doi:10.1200/JCO.2012.43.2229 10.1200/JCO.2012.43.2229CrossRefPubMed

10.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010, 120(6):707–718. doi:10.1007/s00401–010–0781-z 10.1007/s00401-010-0781-zCrossRefPubMed

11.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90(19):1473–1479. 10.1093/jnci/90.19.1473CrossRefPubMed

12.

van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM: Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003, 97(5):1276–1284. 10.1002/cncr.11187CrossRefPubMed

13.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds): WHO Classification of Tumours of the Central Nervous System. WHO Organization Classification of Tumours. 4th edition. IARC, Lyon, France, Lyon; 2007.

14.

Jones DT, Ichimura K, Liu L, Pearson DM, Plant K, Collins VP: Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol 2006, 65(11):1049–1058. doi:10.1097/01.jnen.0000240465.33628.87 10.1097/01.jnen.0000240465.33628.87CrossRefPubMedPubMedCentral

15.

Vogazianou AP, Chan R, Backlund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K: Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol 2010, 12(7):664–678. doi:10.1093/neuonc/nop075 10.1093/neuonc/nop075CrossRefPubMedPubMedCentral

16.

Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009, 11(4):341–347. doi:10.1215/15228517–2009–025 10.1215/15228517-2009-025CrossRefPubMedPubMedCentral

17.

Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000, 60(2):417–424.PubMed

18.

Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008, 68(21):8673–8677. doi:10.1158/0008–5472.CAN-08–2097 10.1158/0008-5472.CAN-08-2097CrossRefPubMedPubMedCentral

19.

Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K: A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 2011, 121(5):651–661. doi:10.1007/s00401–011–0803–5 10.1007/s00401-011-0803-5CrossRefPubMed

20.

Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Backlund LM, Collins VP, Ichimura K: MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumours with IDH1 or IDH2 mutations. J Int Cancer 2011, 135(5):1104–1113.

21.

Royston P, Sauerbrei W: Multivariable Model-building: A prgamatic approach to regression analysis based on fractional polynomials for modelling continuous variables. John Wiley & Sons, London; 2008.CrossRef

22.

Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C: Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009, 101(1):124–131. doi:10.1038/sj.bjc.6605127 10.1038/sj.bjc.6605127CrossRefPubMedPubMedCentral

23.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D: Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 2009, 115(20):4783–4794. doi:10.1002/cncr.24546 10.1002/cncr.24546CrossRefPubMed

24.

Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991, 51(8):2164–2172.PubMed

25.

Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP: Amplification of multiple genes from chromosomal region 12q13–14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994, 54(16):4299–4303.PubMed

26.

Collaborators CGARN: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061–1068. doi:10.1038/nature07385 10.1038/nature07385CrossRef

27.

James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins VP, Cavenee WK: Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988, 48(19):5546–5551.PubMed

28.

Ichimura K, Vogazianou AP, Liu L, Pearson DM, Backlund LM, Plant K, Baird K, Langford CF, Gregory SG, Collins VP: 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene 2008, 27(14):2097–2108. doi:10.1038/sj.onc.1210848 10.1038/sj.onc.1210848CrossRefPubMed

29.

Ekstrand AJ, Sugawa N, James CD, Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A 1992, 89(10):4309–4313. 10.1073/pnas.89.10.4309CrossRefPubMedPubMedCentral

30.

Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994, 9(8):2313–2320.PubMed

31.

Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002, 8(8):2725–2734.PubMed

32.

Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96(3):766–776. doi:10.1111/j.1471–4159.2005.03583.x 10.1111/j.1471-4159.2005.03583.xCrossRefPubMed

33.

Russell SJ, Ye YW, Waber PG, Shuford M, Schold SC Jr, Nisen PD: p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer 1995, 75(6):1339–1342. 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-FCrossRefPubMed

34.

Xu GW, Mymryk JS, Cairncross JG: Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol 2005, 74(2):141–149. doi:10.1007/s11060–004–6601–3 10.1007/s11060-004-6601-3CrossRefPubMed

35.

Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012, 124(4):547–560. doi:10.1007/s00401–012–1016–2 10.1007/s00401-012-1016-2CrossRefPubMedPubMedCentral

36.

Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2010, 6(1):39–51. doi:10.1038/nrneurol.2009.197 10.1038/nrneurol.2009.197CrossRefPubMed

37.

Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G: Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012, 14(Suppl 4):iv100-iv108. doi:10.1093/neuonc/nos206CrossRefPubMedPubMedCentral

38.

Mason S, McDonald K: MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J Cancer Res Clin Oncol 2012, 138(11):1789–1797. doi:10.1007/s00432–012–1312–1 10.1007/s00432-012-1312-1CrossRefPubMed

Title: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial
Authors: Vincent Peter Collins
Koichi Ichimura
Ying Di
Danita Pearson
Ray Chan
Lindsay C Thompson
Rhian Gabe
Michael Brada
Sally P Stenning
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Acta Neuropathologica Communications / Issue 1/2014
Electronic ISSN: 2051-5960
DOI: https://doi.org/10.1186/2051-5960-2-68

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

RETRACTED ARTICLE: A new inducible transgenic mouse model for C9orf72-associated GGGGCC repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and FTD

Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA

Adenosine triphosphate drives head and neck cancer pain through P2X2/3 heterotrimers

The prion protein protease sensitivity, stability and seeding activity in variably protease sensitive prionopathy brain tissue suggests molecular overlaps with sporadic Creutzfeldt-Jakob disease

Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis

Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice